Cargando…

Unprecedented Therapeutic Potential with a Combination of A(2A)/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease

In Parkinson's disease, the long-term use of dopamine replacing agents is associated with the development of motor complications; therefore, there is a need for non-dopaminergic drugs. This study evaluated the potential therapeutic impact of six different NR2B and A(2A) receptor antagonists giv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michel, Anne, Downey, Patrick, Nicolas, Jean-Marie, Scheller, Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267740/ https://www.ncbi.nlm.nih.gov/pubmed/25513815 http://dx.doi.org/10.1371/journal.pone.0114086

Ejemplares similares

Behavioural Assessment of the A(2a)/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs
por: Michel, Anne, et al.
Publicado: (2015)

Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway
por: Yan, Aijuan, et al.
Publicado: (2021)

Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease
por: dos Santos Pereira, Maurício, et al.
Publicado: (2021)

Changes in Excitability Properties of Ventromedial Motor Thalamic Neurons in 6-OHDA Lesioned Mice
por: Bichler, Edyta K., et al.
Publicado: (2021)

T-Lymphocyte Deficiency Exacerbates Behavioral Deficits in the 6-OHDA Unilateral Lesion Rat Model for Parkinson’s Disease
por: Wheeler, Christopher J, et al.
Publicado: (2014)

The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson’s Disease Model
por: Jia, Ruru, et al.
Publicado: (2023)

Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson's disease models
por: Wang, Wen-Wen, et al.
Publicado: (2021)

Palmitate and Stearate are Increased in the Plasma in a 6-OHDA Model of Parkinson’s Disease
por: Shah, Anuri, et al.
Publicado: (2019)

A Focus on Unusual ECL2 Interactions Yields β(2)‐Adrenergic Receptor Antagonists with Unprecedented Scaffolds
por: Scharf, Magdalena M., et al.
Publicado: (2020)

Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone
por: Rodrigues, Laís D., et al.
Publicado: (2019)

Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson’s Disease
por: Barata-Antunes, Sandra, et al.
Publicado: (2020)

Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson’s disease
por: Yu, Jianjun, et al.
Publicado: (2023)

Glucose Homeostasis Is Not Affected in a Murine Model of Parkinson’s Disease Induced by 6-OHDA
por: Gomes, Felipe Azevedo, et al.
Publicado: (2019)

Neurodegenerative Shielding by Curcumin and Its Derivatives on Brain Lesions Induced by 6-OHDA Model of Parkinson's Disease in Albino Wistar Rats
por: Agrawal, Shyam Sunder, et al.
Publicado: (2012)

Effects of Treadmill Exercise on the Recovery of Dopaminergic Neuron Loss and Muscle Atrophy in the 6-OHDA Lesioned Parkinson's Disease Rat Model
por: Choe, Myoung-Ae, et al.
Publicado: (2012)

Effect of Adenosine A(2A) Receptor Antagonists and l-DOPA on Hydroxyl Radical, Glutamate and Dopamine in the Striatum of 6-OHDA-Treated Rats
por: Gołembiowska, Krystyna, et al.
Publicado: (2011)

Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I, et al.
Publicado: (2015)

Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson’s disease
por: Collins, Louise M, et al.
Publicado: (2014)

Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA
por: Tu, Li, et al.
Publicado: (2019)

Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis
por: Walker, Matthew D, et al.
Publicado: (2013)

The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson’s Disease
por: Yu, Hao, et al.
Publicado: (2021)

Crystal structure of adenosine A(2A) receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction
por: Claff, Tobias, et al.
Publicado: (2023)

Adenosine A(2A) Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson’s Mice
por: Yin, Su-bing, et al.
Publicado: (2017)

Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson’s Disease Models
por: Ham, Hyeon Joo, et al.
Publicado: (2022)

Therapeutic function of a novel rat induced pluripotent stem cell line in a 6-OHDA-induced rat model of Parkinson's disease
por: Xu, Jiajia, et al.
Publicado: (2022)

Erratum to: Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I., et al.
Publicado: (2015)

6-OHDA-Induced Changes in Colonic Segment Contractility in the Rat Model of Parkinson's Disease
por: Murillo, Maria Del Pilar, et al.
Publicado: (2023)

Acyl-Ghrelin Attenuates Neurochemical and Motor Deficits in the 6-OHDA Model of Parkinson’s Disease
por: Rees, Daniel, et al.
Publicado: (2022)

L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
por: Huang, Yixian, et al.
Publicado: (2018)

Transplantation of Deprenyl-Induced Tyrosine Hydroxylase-Positive Cells Improves 6-OHDA-Lesion Rat Model of Parkinson’s Disease: Behavioral and Immunohistochemical Evaluation
por: Haji Ghasem Kashani, Maryam, et al.
Publicado: (2013)

Chronic Cerebral Hypoperfusion Aggravates Parkinson's Disease Dementia-Like Symptoms and Pathology in 6-OHDA-Lesioned Rat through Interfering with Sphingolipid Metabolism
por: Fan, Yaohua, et al.
Publicado: (2022)

Streichquartett Nr. 1 ; Streichquartett Nr. 2
por: Ligeti, György, 1923-
Publicado: (1988)

Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
por: Lu, Di-Sheng, et al.
Publicado: (2018)

Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson’s disease evaluated with multimodal MRI
por: Perlbarg, Vincent, et al.
Publicado: (2018)

Fraternine, a Novel Wasp Peptide, Protects against Motor Impairments in 6-OHDA Model of Parkinsonism
por: Biolchi, Andréia Mayer, et al.
Publicado: (2020)

Carbidopa-Based Modulation of the Functional Effect of the AAV2-hAADC Gene Therapy in 6-OHDA Lesioned Rats
por: Ciesielska, Agnieszka, et al.
Publicado: (2015)

Unprecedented
Publicado: (1898)

Therapeutic Effect of Hydrogen Sulfide-Releasing L-Dopa Derivative ACS84 on 6-OHDA-Induced Parkinson’s Disease Rat Model
por: Xie, Li, et al.
Publicado: (2013)

Galangin Exhibits Neuroprotective Effects in 6-OHDA-Induced Models of Parkinson’s Disease via the Nrf2/Keap1 Pathway
por: Chen, Qiu-Xu, et al.
Publicado: (2022)

Identification of Bilateral Changes in TID1 Expression in the 6-OHDA Rat Model of Parkinson's Disease
por: Proft, Juliane, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ok24bm8jq4s8nu8rg9ec50rtas